Meng Wang^*1, Xin Wang^†1, Yuan Li^‡1, Qiang Xiao^§, Xiao-Hai Cui^*, Guo-Dong Xiao^*, Ji-Chang Wang^¶, Chong-Wen Xu^#, Hong Ren^*, Dapeng Liu^*

Oncology Research, Vol.27, No.9, pp. 987-995, 2019, DOI:10.3727/096504018X15424918479652

Abstract The aim of this study was to investigate the potential biological activities of nutlin-3 in the regulation of growth and proliferation of non-small cell lung cancer (NSCLC) stem cells (CSCs), which may help in sensitizing to axitinib-induced apoptosis. Nutlin-3 induction of p53 expression was used to test its role in controlling the cell division pattern and apoptosis of NSCLC cells. A549 cells and H460 cells were pretreated with nutlin-3 and then treated with either an Akt1 activator or shRNA-GSK3 , to investigate the potential role of p53 sensitization in the biological effects of axitinib. We… More >

Vinitha Richard, Rajesh Raju, Aswathy Mary Paul, Reshmi Girijadevi, Thankayyan Retnabai Santhosh Kumar, Madhavan Radhakrishna Pillai

Oncology Research, Vol.26, No.1, pp. 17-26, 2018, DOI:10.3727/096504017X14881490607028

Abstract This study is an integrated analysis of the transcriptome profile microRNA (miRNA) and its experimentally validated mRNA targets differentially expressed in the tumorigenic stem-like fraction of oral squamous cell carcinoma (OSCC). We had previously reported the coexistence of multiple drug-resistant tumorigenic fractions, termed side population (SP1, SP2, and MP2), and a nontumorigenic fraction, termed main population (MP1), in oral cancer. These fractions displayed a self-renewal, regenerative potential and expressed known stemness-related cell surface markers despite functional differences. Flow cytometrically sorted pure fractions of SP1 and MP1 cells were subjected to differential expression analysis of both… More >

Qifang Long^*, Weipei Zhu^*, Jundong Zhou^†, Jinchang Wu^†, Weixian Lu^‡, Cui Zheng^‡, Dongmei Zhou^‡, Ling Yu^‡, Ru Yang^‡

Oncology Research, Vol.25, No.4, pp. 595-603, 2017, DOI:10.3727/096504016X14765492198706

Abstract Ovarian cancer is one of the most lethal malignant gynecologic tumors with a high relapse rate worldwide. Cancer stem cells (CSCs) have been identified in ovarian cancer and other malignant tumors as a small population of cells that are capable of self-renewal and multidifferentiation. CD133⁺ ovarian CSCs have been reported to be more tumorigenic and more resistant to chemotherapeutic treatment. Thus, CD133 has emerged as one of the most promising therapeutic markers for ovarian cancer treatment. In the current study, we constructed a recombinant adenovirus Cre/loxP regulation system to selectively introduce truncated Bid (tBid) expression specifically… More >